About us Membership Investor Awareness Advertise Publish News
Rated as a top Investment site for 2025!

                               

Biotech and Medical Tech Stocks Directory (Updated for 2025)

Aadi Bioscience, Inc. (NASDAQ: AADI)

• Description: Aadi Bioscience, Inc. is a biopharmaceutical company developing precision therapies for genetically defined cancers. Its lead product, FYARRO (sirolimus protein-bound particles), is approved for advanced malignant PEComa, with ongoing trials targeting mTOR-driven tumors in 2025.

Abeona Therapeutics Inc. (NASDAQ: ABEO)

• Description: Abeona Therapeutics Inc. is a clinical-stage company focused on gene and cell therapies for serious diseases. Its lead candidate, pz-cel (prademagene zamikeracel), targets recessive dystrophic epidermolysis bullosa (RDEB) and is in late-stage development with potential approval in 2025.

Acasti Pharma Inc. (NASDAQ: ACST)

• Description: Acasti Pharma Inc. is a late-stage biopharma developing therapies for rare and orphan diseases. GTX-104, an IV nimodipine for subarachnoid hemorrhage, completed a successful Phase 3 trial in 2025, advancing toward U.S. regulatory submission.

Accuray Incorporated (NASDAQ: ARAY)

• Description: Accuray Incorporated develops robotic radiosurgery systems like CyberKnife and TomoTherapy, providing precise radiation treatments for cancer and neurological conditions, with over 1,000 systems installed globally.

Acorda Therapeutics, Inc. (NASDAQ: ACOR)

• Description: Acorda Therapeutics, Inc. focuses on neurological disorders, marketing INBRIJA (levodopa inhalation powder) for Parkinson’s disease and FAMPYRA (fampridine) for MS-related walking issues, with a pipeline exploring new CNS indications.

Aethlon Medical, Inc. (NASDAQ: AEMD)

• Description: Aethlon Medical, Inc. develops the Hemopurifier, a device to remove viruses and exosomes from blood. With FDA Breakthrough Device designations for cancer and viral infections, it’s advancing clinical trials in 2025.

Affimed N.V. (NASDAQ: AFMD)

• Description: Affimed N.V. is a clinical-stage immuno-oncology company developing innate cell engagers (ICE). Its lead candidate, AFM13, targets CD30-positive lymphomas and is in Phase 2 trials, with combination therapies progressing.

AgeX Therapeutics, Inc. (NYSE American: AGE)

• Description: AgeX Therapeutics, Inc. focuses on regenerative medicine using its UniverCyte™ platform for allogeneic cell therapies. It targets age-related degenerative diseases, with preclinical programs nearing clinical stages in 2025.

Aileron Therapeutics, Inc. (NASDAQ: ALRN)

• Description: Aileron Therapeutics, Inc. develops precision medicines for p53-mutated cancers. ALRN-6924, a chemoprotective agent, is in trials to reduce chemotherapy toxicity, with data expected in 2025.

Alimera Sciences, Inc. (NASDAQ: ALIM)

• Description: Alimera Sciences, Inc. specializes in retinal health, marketing ILUVIEN (fluocinolone acetonide intravitreal implant) for diabetic macular edema and uveitis, expanding its global footprint in 2025.

AlloVir, Inc. (NASDAQ: ALVR)

• Description: AlloVir, Inc. develops allogeneic T-cell therapies for viral diseases in immunocompromised patients. Its multi-virus targeting candidates are in Phase 3 trials post-transplantation, with results anticipated in 2025.

Alpha Tau Medical Ltd. (NASDAQ: DRTS)

• Description: Alpha Tau Medical Ltd. develops Alpha DaRT™ (Diffusing Alpha-emitters Radiation Therapy) for solid tumors. Clinical trials for skin, breast, and pancreatic cancers continue, offering targeted radiotherapy advancements.

Alterity Therapeutics Limited (NASDAQ: ATHE)

• Description: Alterity Therapeutics Limited focuses on neurodegenerative diseases, with ATH434 in Phase 2 trials for Multiple System Atrophy (MSA), aiming to alter disease progression using novel small molecules.

Alto Neuroscience, Inc. (NYSE: ANRO)

• Description: Alto Neuroscience, Inc. develops precision psychiatry treatments using AI-driven biomarkers. Its pipeline for depression and PTSD is advancing through clinical stages, with key data readouts in 2025.

Amicus Therapeutics, Inc. (NASDAQ: FOLD)

• Description: Amicus Therapeutics, Inc. develops therapies for rare diseases, marketing Galafold (migalastat) for Fabry disease and advancing AT-GAA for Pompe disease, with global approvals expanding in 2025.

AngioDynamics, Inc. (NASDAQ: ANGO)

• Description: AngioDynamics, Inc. designs medical devices for vascular access and oncology, with NanoKnife for irreversible electroporation gaining traction in minimally invasive cancer treatments in 2025.

Anixa Biosciences, Inc. (NASDAQ: ANIX)

• Description: Anixa Biosciences, Inc. focuses on cancer diagnostics and immunotherapy. Cchek™ detects early-stage cancer, while its CAR-T therapy for ovarian cancer progresses in clinical trials, targeting milestones in 2025.

Annaly Capital Management, Inc. (NYSE: NLY)

• Description: Annaly Capital Management, Inc., a diversified capital manager, invests in healthcare and biotech through subsidiaries, supporting medical tech innovations as part of its broader portfolio in 2025.

Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)

• Description: Apellis Pharmaceuticals, Inc. targets the complement system, marketing SYFOVRE (pegcetacoplan) for geographic atrophy and EMPAVELI for PNH, with further indications advancing in trials.

Applied Therapeutics, Inc. (NASDAQ: APLT)

• Description: Applied Therapeutics, Inc. develops treatments for cardiometabolic and rare diseases. Govorestat, targeting galactosemia, is in late-stage trials with a potential FDA filing in 2025.

Aravive, Inc. (NASDAQ: ARAV)

• Description: Aravive, Inc. focuses on oncology with batiraxcept targeting the GAS6-AXL pathway. It’s in Phase 2/3 trials for ovarian and pancreatic cancers, aiming to improve survival outcomes.

Arbutus Biopharma Corporation (NASDAQ: ABUS)

• Description: Arbutus Biopharma Corporation develops therapies for chronic hepatitis B. Imdusiran, an RNAi candidate, is in Phase 2 trials, targeting functional cures in combination therapies by 2025.

Arcus Biosciences, Inc. (NYSE: RCUS)

• Description: Arcus Biosciences, Inc. develops cancer immunotherapies with domvanalimab (anti-TIGIT) and etrumadenant in Phase 3 trials for lung and GI cancers, partnered with Gilead Sciences.

Ardelyx, Inc. (NASDAQ: ARDX)

• Description: Ardelyx, Inc. focuses on GI and cardiorenal therapies, marketing IBSRELA (tenapanor) for IBS-C and XPHOZAH for hyperphosphatemia, with expanded indications in development.

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

• Description: Arena Pharmaceuticals, Inc., now under Pfizer, develops small molecule drugs like etrasimod for ulcerative colitis, advancing its immune-mediated disease pipeline in 2025.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)

• Description: Arrowhead Pharmaceuticals, Inc. develops RNAi therapeutics, with plozasiran for hypertriglyceridemia and zodasiran for dyslipidemia in late-stage trials, targeting approvals by 2025.

AstraZeneca PLC (NASDAQ: AZN)

• Description: AstraZeneca PLC is a global biopharma leader in oncology and respiratory diseases, marketing ENHERTU and IMFINZI, with a robust pipeline advancing in 2025.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA)

• Description: Atara Biotherapeutics, Inc. develops allogeneic T-cell therapies, with tab-cel nearing U.S. approval for EBV+ PTLD following successful Phase 3 results in 2025.

Atea Pharmaceuticals, Inc. (NASDAQ: AVIR)

• Description: Atea Pharmaceuticals, Inc. focuses on antiviral therapies for RNA viruses, with bemnifosbuvir in Phase 3 trials for hepatitis C, eyeing broader applications in 2025.

Athersys, Inc. (NASDAQ: ATHX)

• Description: Athersys, Inc. develops MultiStem cell therapy for neurological and inflammatory conditions, advancing trials for stroke and ARDS with partnerships in 2025.

Atossa Therapeutics, Inc. (NASDAQ: ATOS)

• Description: Atossa Therapeutics, Inc. focuses on breast cancer, with (Z)-endoxifen in Phase 2 trials for prevention and treatment, leveraging oral SERM technology in 2025.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH)

• Description: Aurinia Pharmaceuticals Inc. develops autoimmune therapies, marketing LUPKYNIS (voclosporin) for lupus nephritis, with research expanding into broader indications in 2025.

Autolus Therapeutics plc (NASDAQ: AUTL)

• Description: Autolus Therapeutics plc develops CAR-T therapies, with obecabtagene autoleucel (obe-cel) in pivotal trials for ALL, targeting potential approval in 2025.

Avadel Pharmaceuticals plc (NASDAQ: AVDL)

• Description: Avadel Pharmaceuticals plc focuses on sleep disorders, marketing LUMRYZ™ (sodium oxybate) for narcolepsy and expanding its sleep medicine portfolio in 2025.

AVEO Oncology (NASDAQ: AVEO)

• Description: AVEO Oncology, now part of LG Chem, markets FOTIVDA (tivozanib) for renal cell carcinoma, with its oncology portfolio growing under LG Chem in 2025.

Axsome Therapeutics, Inc. (NASDAQ: AXSM)

• Description: Axsome Therapeutics, Inc. develops CNS therapies, marketing AUVELITY for depression and SUNOSI for narcolepsy, with a pipeline targeting migraines and Alzheimer’s.

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC.TO)

• Description: Bausch Health Companies Inc. develops pharmaceuticals across gastroenterology and neurology, marketing XIFAXAN and advancing its specialty portfolio in 2025.

Baxter International Inc. (NYSE: BAX)

• Description: Baxter International Inc. provides medical products for acute and chronic care, including dialysis and IV solutions, with renal care innovations progressing in 2025.

Becton, Dickinson and Company (NYSE: BDX)

• Description: Becton, Dickinson and Company (BD) develops diagnostics and drug delivery systems, with the BD FACSDiscover™ S8 Cell Sorter advancing research capabilities in 2025.

BeiGene, Ltd. (NASDAQ: BGNE)

• Description: BeiGene, Ltd. develops cancer therapies, marketing BRUKINSA (zanubrutinib) for hematologic malignancies and advancing its oncology pipeline with late-stage trials.

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM)

• Description: Bellicum Pharmaceuticals, Inc. develops cellular immunotherapies, with BPX-601 CAR-T therapy in trials for solid tumors, featuring a safety switch for enhanced control.

Bellerophon Therapeutics, Inc. (NASDAQ: BLPH)

• Description: Bellerophon Therapeutics, Inc. focuses on cardiopulmonary diseases, with INOpulse nitric oxide therapy in trials for pulmonary hypertension and fibrotic lung diseases.

BeyondSpring Inc. (NASDAQ: BYSI)

• Description: BeyondSpring Inc. develops cancer therapies, with plinabulin in late-stage trials for chemotherapy-induced neutropenia and NSCLC, targeting approvals in 2025.

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)

• Description: BioCryst Pharmaceuticals, Inc. develops oral drugs for rare diseases, marketing ORLADEYO for hereditary angioedema and advancing complement-mediated disease therapies.

BioDelivery Sciences International, Inc. (NASDAQ: BDSI)

• Description: BioDelivery Sciences International, Inc., now part of Collegium Pharmaceutical, markets BELBUCA for chronic pain, enhancing drug delivery with its BEMA technology in 2025.

Biofrontera Inc. (NASDAQ: BFRI)

• Description: Biofrontera Inc. focuses on dermatology, marketing Ameluz for photodynamic therapy of actinic keratosis, with expanded U.S. adoption for skin cancer treatment in 2025.

Biohaven Ltd. (NYSE: BHVN)

• Description: Biohaven Ltd. develops neurological therapies, marketing NURTEC ODT for migraines and advancing candidates for OCD and spinocerebellar ataxia in late-stage trials.

BioLineRx Ltd. (NASDAQ: BLRX)

• Description: BioLineRx Ltd. develops oncology therapies, with APHEXDA (motixafortide) approved for stem cell mobilization in multiple myeloma and further trials ongoing.

BiomX Inc. (NYSE American: PHGE)

• Description: BiomX Inc. develops phage therapies for pathogenic bacteria, with BX004 in Phase 2 trials for cystic fibrosis-related lung infections, leveraging microbiome technology.

BioNTech SE (NASDAQ: BNTX)

• Description: BioNTech SE pioneers mRNA therapies, co-developing COMIRNATY with Pfizer and advancing cancer immunotherapies and infectious disease vaccines in 2025.

Bio-Path Holdings, Inc. (NASDAQ: BPTH)

• Description: Bio-Path Holdings, Inc. develops DNAbilize antisense RNAi therapies, with prexigebersen in Phase 2 trials for AML and potential expansion to solid tumors in 2025.

BioSig Technologies, Inc. (NASDAQ: BSGM)

• Description: BioSig Technologies, Inc. develops bioelectronic technologies, with PURE EP™ enhancing cardiac electrophysiology procedures, gaining clinical traction in 2025.

BioXcel Therapeutics, Inc. (NASDAQ: BTAI)

• Description: BioXcel Therapeutics, Inc. uses AI for neuroscience and oncology therapies, marketing IGALMI™ for agitation and advancing BXCL701 for pancreatic cancer.

Black Diamond Therapeutics, Inc. (NASDAQ: BDTX)

• Description: Black Diamond Therapeutics, Inc. develops precision oncology therapies, with BDTX-1535 in Phase 2 trials for EGFR-mutant lung cancer and glioblastoma in 2025.

Blueprint Medicines Corporation (NASDAQ: BPMC)

• Description: Blueprint Medicines Corporation develops precision therapies, marketing AYVAKIT for GIST and advancing zanzalintinib for lung cancer and mastocytosis.

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI)

• Description: BrainStorm Cell Therapeutics Inc. develops autologous stem cell therapies, with NurOwn in late-stage trials for ALS and potential expansion to other CNS disorders.

BridgeBio Pharma, Inc. (NASDAQ: BBIO)

• Description: BridgeBio Pharma, Inc. targets genetic diseases, with acoramidis in late-stage trials for transthyretin amyloid cardiomyopathy and a broad pipeline for rare disorders.

Bristol Myers Squibb (NYSE: BMY)

• Description: Bristol Myers Squibb is a global biopharma leader, marketing OPDIVO and REBLOZYL, with a robust pipeline in oncology and immunology advancing in 2025.

C4 Therapeutics, Inc. (NASDAQ: CCCC)

• Description: C4 Therapeutics, Inc. develops protein degradation therapies, with CFT7455 and CFT1946 in Phase 1/2 trials for multiple myeloma and solid tumors.

Caladrius Biosciences, Inc. (NASDAQ: CLBS)

• Description: Caladrius Biosciences, Inc., now Lisata Therapeutics, develops cellular therapies, with LSTA1 in Phase 1b/2 trials enhancing tumor penetration for pancreatic cancer.

Calithera Biosciences, Inc. (NASDAQ: CALA)

• Description: Calithera Biosciences, Inc. develops small molecule therapies, with CB-839 (telaglenastat) in trials for renal cell carcinoma and strategic partnerships in 2025.

Cardiff Oncology, Inc. (NASDAQ: CRDF)

• Description: Cardiff Oncology, Inc. develops onvansertib, a PLK1 inhibitor, for KRAS-mutated cancers, in Phase 2 trials for colorectal and pancreatic cancers.

Cardinal Health, Inc. (NYSE: CAH)

• Description: Cardinal Health, Inc. supports biotech with drug distribution and medical products, enhancing healthcare delivery with logistics and specialty solutions in 2025.

Cardiol Therapeutics Inc. (NASDAQ: CRDL)

• Description: Cardiol Therapeutics Inc. develops anti-inflammatory therapies, with CardiolRx™ in Phase 2/3 trials for myocarditis and heart failure in 2025.

CareDx, Inc. (NASDAQ: CDNA)

• Description: CareDx, Inc. provides diagnostic solutions for transplant patients, with AlloSure and AlloMap monitoring organ rejection, expanding applications in 2025.

Caribou Biosciences, Inc. (NASDAQ: CRBU)

• Description: Caribou Biosciences, Inc. develops CRISPR-edited CAR-T therapies, with CB-010 in Phase 1 trials for B-cell malignancies showing early promise.

Cassava Sciences, Inc. (NASDAQ: SAVA)

• Description: Cassava Sciences, Inc. targets Alzheimer’s with simufilam in Phase 3 trials, aiming to address amyloid-beta pathology with potential 2025 outcomes.

Castle Biosciences, Inc. (NASDAQ: CSTL)

• Description: Castle Biosciences, Inc. develops diagnostic tests for skin cancers, with DecisionDx guiding treatment decisions and expanding into new indications in 2025.

Celldex Therapeutics, Inc. (NASDAQ: CLDX)

• Description: Celldex Therapeutics, Inc. develops immunotherapies, with barzolvolimab in Phase 2 trials for mast cell disorders and potential broader applications.

Cellectar Biosciences, Inc. (NASDAQ: CLRB)

• Description: Cellectar Biosciences, Inc. develops phospholipid drug conjugates, with iopofosine I 131 in pivotal trials for Waldenström’s macroglobulinemia, targeting approval in 2025.

Celsius Therapeutics, Inc. (NASDAQ: CLSH)

• Description: Celsius Therapeutics, Inc. uses single-cell genomics for precision therapies in autoimmune diseases and cancer, advancing preclinical programs toward trials in 2025.

Centogene N.V. (NASDAQ: CNTG)

• Description: Centogene N.V. provides genetic diagnostics for rare diseases, with its CENTOGENE Biodatabank supporting drug development through partnerships in 2025.

Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)

• Description: Cerevel Therapeutics Holdings, Inc., now part of AbbVie, develops neuroscience therapies, with emraclidine in Phase 2 trials for schizophrenia under AbbVie’s oversight.

Cerus Corporation (NASDAQ: CERS)

• Description: Cerus Corporation develops the INTERCEPT Blood System to enhance blood safety, expanding its transfusion medicine applications globally in 2025.

ChemoCentryx, Inc. (NASDAQ: CCXI)

• Description: ChemoCentryx, Inc., now part of Amgen, markets TAVNEOS for ANCA-associated vasculitis, bolstering Amgen’s inflammatory disease portfolio in 2025.

Chimerix, Inc. (NASDAQ: CMRX)

• Description: Chimerix, Inc., acquired by Jazz Pharmaceuticals, develops antiviral therapies, with dordaviprone in trials for H3 K27M-mutant glioma, nearing FDA review in 2025.

Clene Inc. (NASDAQ: CLNN)

• Description: Clene Inc. develops nanotherapeutics, with CNM-Au8 in Phase 3 trials for ALS and MS, aiming to improve cellular energy and neurological function.

Clover Health Investments, Corp. (NASDAQ: CLOV)

• Description: Clover Health Investments, Corp. leverages AI-driven platforms for Medicare Advantage healthcare, enhancing patient outcomes with medical tech in 2025.

Co-Diagnostics, Inc. (NASDAQ: CODX)

• Description: Co-Diagnostics, Inc. develops molecular diagnostics, with its Co-Dx PCR platform expanding at-home testing for infectious diseases globally in 2025.

Cognition Therapeutics, Inc. (NASDAQ: CGTX)

• Description: Cognition Therapeutics, Inc. develops small molecule therapies for neurodegenerative diseases, with CT1812 in Phase 2 trials for Alzheimer’s targeting synaptic protection.

Compugen Ltd. (NASDAQ: CGEN)

• Description: Compugen Ltd. uses computational biology for cancer immunotherapies, with COM701 in Phase 1/2 trials for solid tumors, advancing with partnerships in 2025.

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE)

• Description: Concert Pharmaceuticals, Inc., now part of Sun Pharma, markets CTP-543 (deuruxolitinib) for alopecia areata, enhancing its portfolio with deuterium chemistry in 2025.

Corcept Therapeutics Incorporated (NASDAQ: CORT)

• Description: Corcept Therapeutics Incorporated develops cortisol modulators, marketing KORLYM for Cushing’s syndrome and advancing relacorilant for adrenal cancer in Phase 3 trials.

Cortexyme, Inc. (NASDAQ: CRTX)

• Description: Cortexyme, Inc., now Quince Therapeutics, targets rare diseases with NOV004 in preclinical development for osteogenesis imperfecta, shifting focus in 2025.

Cue Biopharma, Inc. (NASDAQ: CUE)

• Description: Cue Biopharma, Inc. develops Immuno-STAT™ biologics for cancer and autoimmune diseases, with CUE-101 in Phase 1 trials for head and neck cancer.

CureVac N.V. (NASDAQ: CVAC)

• Description: CureVac N.V. develops mRNA-based vaccines and therapeutics, with CVnCoV in late-stage trials for COVID-19 and oncology applications expanding in 2025.

Cymabay Therapeutics, Inc. (NASDAQ: CBAY)

• Description: Cymabay Therapeutics, Inc., now part of Gilead, markets seladelpar for primary biliary cholangitis, enhancing Gilead’s liver disease offerings in 2025.

Cytokinetics, Incorporated (NASDAQ: CYTK)

• Description: Cytokinetics, Incorporated develops muscle-targeted therapies, with aficamten in Phase 3 for hypertrophic cardiomyopathy, nearing potential approval in 2025.

CytomX Therapeutics, Inc. (NASDAQ: CXTM)

• Description: CytomX Therapeutics, Inc. develops Probody therapeutics, with CX-904 in Phase 1/2 trials with Amgen for solid tumors, targeting precision oncology.

Daré Bioscience, Inc. (NASDAQ: DARE)

• Description: Daré Bioscience, Inc. focuses on women’s health, with Ovaprene and Sildenafil Cream in trials for contraception and female sexual arousal disorder, respectively.

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)

• Description: Day One Biopharmaceuticals, Inc. develops pediatric cancer therapies, with tovorafenib in pivotal trials for relapsed low-grade glioma, targeting approval in 2025.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)

• Description: Deciphera Pharmaceuticals, Inc., now part of Ono Pharmaceutical, markets QINLOCK for GIST, with its kinase inhibitor platform expanding under Ono in 2025.

Denali Therapeutics Inc. (NASDAQ: DNLI)

• Description: Denali Therapeutics Inc. develops therapies for neurodegenerative diseases, with DNL310 in Phase 2/3 trials for Hunter syndrome and candidates for Alzheimer’s advancing.

DermTech, Inc. (NASDAQ: DMTK)

• Description: DermTech, Inc. offers non-invasive genomic tests for skin cancer, with its DermTech Melanoma Test expanding early detection in dermatology practices in 2025.

Durect Corporation (NASDAQ: DRRX)

• Description: Durect Corporation develops therapies for chronic pain and liver diseases, with larsucosterol in Phase 3 trials for alcohol-associated hepatitis, targeting breakthrough status in 2025.

Dyadic International, Inc. (NASDAQ: DYAI)

• Description: Dyadic International, Inc. uses its C1 fungal platform for protein production, advancing vaccine and therapeutic candidates like DYAI-100 in partnerships for biomanufacturing.

Dynavax Technologies Corporation (NASDAQ: DVAX)

• Description: Dynavax Technologies Corporation develops vaccines with CpG 1018 adjuvant, marketing HEPLISAV-B and expanding oncology applications in 2025.

Edesa Biotech, Inc. (NASDAQ: EDSA)

• Description: Edesa Biotech, Inc. develops therapies for inflammatory diseases, with EB05 in Phase 3 trials for ARDS, aiming to address critical care needs in 2025.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX)

• Description: Edgewise Therapeutics, Inc. targets muscle diseases, with sevasemten in Phase 3 trials for Becker muscular dystrophy and preclinical work for Duchenne in 2025.

Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR)

• Description: Eiger BioPharmaceuticals, Inc. develops therapies for rare metabolic diseases, marketing Zokinvy for progeria and advancing trials for hepatitis delta virus.

Eldorado Gold Corporation (NYSE: EGO) (TSX: ELD.TO)

• Description: Eldorado Gold Corporation, a mining company, indirectly supports biotech through investments, funding medical tech innovations with its resources in 2025.

Eledon Pharmaceuticals, Inc. (NASDAQ: ELDN)

• Description: Eledon Pharmaceuticals, Inc. develops immune-modulating therapies, with tegoprubart in Phase 2 trials for transplant rejection and ALS, improving patient outcomes.

Elevation Oncology, Inc. (NASDAQ: ELEV)

• Description: Elevation Oncology, Inc. focuses on precision oncology, with seribantumab in Phase 2 trials for NRG1 fusion-positive tumors and new genomic targets in development.

Eli Lilly and Company (NYSE: LLY)

• Description: Eli Lilly and Company leads in diabetes and oncology, marketing MOUNJARO and advancing Alzheimer’s therapies like donanemab with significant 2025 milestones.

Emergent BioSolutions Inc. (NYSE: EBS)

• Description: Emergent BioSolutions Inc. provides public health solutions, marketing NARCAN and vaccines like ACAM2000, with biodefense contracts growing in 2025.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA)

• Description: Enanta Pharmaceuticals, Inc. develops small molecule drugs for viral infections, with candidates targeting RSV and NASH in clinical trials for 2025.

Endo International plc (NASDAQ: ENDP)

• Description: Endo International plc develops specialty pharmaceuticals, marketing XIAFLEX for Dupuytren’s contracture and advancing pain management therapies in 2025.

Enlivex Therapeutics Ltd. (NASDAQ: ENLV)

• Description: Enlivex Therapeutics Ltd. develops Allocetra™, an allogeneic cell therapy for sepsis and osteoarthritis, with Phase 2 trials progressing in 2025.

Entrada Therapeutics, Inc. (NASDAQ: TRDA)

• Description: Entrada Therapeutics, Inc. develops intracellular therapeutics, with ENTR-601-44 in Phase 1 trials for Duchenne muscular dystrophy using its EEV™ platform.

Esperion Therapeutics, Inc. (NASDAQ: ESPR)

• Description: Esperion Therapeutics, Inc. focuses on lipid management, marketing NEXLETOL and NEXLIZET for cholesterol, with expanded indications in development for 2025.

Eton Pharmaceuticals, Inc. (NASDAQ: ETON)

• Description: Eton Pharmaceuticals, Inc. commercializes treatments for rare diseases, marketing ALKINDI SPRINKLE and advancing pediatric therapies in its pipeline.

Evaxion Biotech A/S (NASDAQ: EVAX)

• Description: Evaxion Biotech A/S uses AI for personalized cancer vaccines, with EVX-01 in Phase 2 trials for melanoma, leveraging its PIONEER™ platform in 2025.

Evelo Biosciences, Inc. (NASDAQ: EVLO)

• Description: Evelo Biosciences, Inc. develops oral microbiome therapies, with EDP1815 in Phase 2 trials for psoriasis and atopic dermatitis, targeting inflammation.

Exact Sciences Corporation (NASDAQ: EXAS)

• Description: Exact Sciences Corporation provides cancer diagnostics, marketing Cologuard and expanding Oncotype DX for precision oncology in 2025.

Exelixis, Inc. (NASDAQ: EXEL)

• Description: Exelixis, Inc. develops oncology therapies, marketing CABOMETYX for RCC and advancing zanzalintinib in late-stage trials for multiple cancers.

Fate Therapeutics, Inc. (NASDAQ: FATE)

• Description: Fate Therapeutics, Inc. develops iPSC-derived cell therapies, with FT819 and FT522 in Phase 1 trials for B-cell malignancies, showing early efficacy in 2025.

FibroGen, Inc. (NASDAQ: FGEN)

• Description: FibroGen, Inc. develops therapies for anemia and fibrosis, marketing roxadustat for CKD anemia and advancing pamrevlumab for pancreatic cancer and IPF.

First Wave BioPharma, Inc. (NASDAQ: FWBI)

• Description: First Wave BioPharma, Inc. focuses on GI diseases, with adrulipase in Phase 2 trials for exocrine pancreatic insufficiency in cystic fibrosis and chronic pancreatitis.

G1 Therapeutics, Inc. (NASDAQ: GTHX)

• Description: G1 Therapeutics, Inc. develops cancer therapies, marketing COSELA (trilaciclib) to reduce chemotherapy-induced myelosuppression, with trials expanding its use in 2025.

Galapagos NV (NASDAQ: GLPG)

• Description: Galapagos NV focuses on novel therapeutics, advancing its CAR-T and small molecule pipeline for oncology and inflammatory diseases, with clinical progress in 2025.

Genocea Biosciences, Inc. (NASDAQ: GNCA)

• Description: Genocea Biosciences, Inc. develops cancer vaccines, with GEN-011, a neoantigen-targeted T-cell therapy, in Phase 1/2 trials for solid tumors, aiming for personalized immunotherapy.

Geron Corporation (NASDAQ: GERN)

• Description: Geron Corporation develops imetelstat, a telomerase inhibitor, in Phase 3 trials for myelodysplastic syndromes and myelofibrosis, targeting potential approval in 2025.

Gilead Sciences, Inc. (NASDAQ: GILD)

• Description: Gilead Sciences, Inc. is a global biopharma leader, marketing BIKTARVY for HIV and TRODELVY for cancer, with a broad pipeline advancing in virology and oncology.

Glaukos Corporation (NYSE: GKOS)

• Description: Glaukos Corporation develops ophthalmic therapies, marketing iStent for glaucoma and expanding its iDose platform for sustained drug delivery in 2025.

Global Blood Therapeutics, Inc. (NASDAQ: GBT)

• Description: Global Blood Therapeutics, Inc., now part of Pfizer, markets OXBRYTA (voxelotor) for sickle cell disease, with Pfizer enhancing its rare disease portfolio in 2025.

GlycoMimetics, Inc. (NASDAQ: GMMI)

• Description: GlycoMimetics, Inc. develops glycobiology-based therapies, with uproleselan in Phase 3 trials for AML, aiming to improve chemotherapy outcomes in 2025.

Gossamer Bio, Inc. (NASDAQ: GOSS)

• Description: Gossamer Bio, Inc. focuses on immunology and respiratory diseases, with seralutinib in Phase 3 trials for pulmonary arterial hypertension, targeting symptom relief.

Gritstone bio, Inc. (NASDAQ: GRTS)

• Description: Gritstone bio, Inc. develops personalized cancer vaccines, with GRANITE in Phase 2/3 trials for colorectal cancer, leveraging neoantigen prediction technology.

Guardant Health, Inc. (NASDAQ: GH)

• Description: Guardant Health, Inc. provides liquid biopsy tests, marketing Guardant360 for cancer profiling and advancing Shield™ for colorectal cancer screening in 2025.

Halozyme Therapeutics, Inc. (NASDAQ: HALO)

• Description: Halozyme Therapeutics, Inc. develops ENHANZE drug delivery technology, enhancing subcutaneous administration for biotech partners, with expanded applications in 2025.

Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY)

• Description: Harmony Biosciences Holdings, Inc. markets WAKIX (pitolisant) for narcolepsy, with trials exploring new indications like Prader-Willi syndrome in 2025.

Heron Therapeutics, Inc. (NASDAQ: HRTX)

• Description: Heron Therapeutics, Inc. develops therapies for pain and nausea, marketing ZYNRELEF for postoperative pain and expanding its supportive care portfolio.

Heska Corporation (NASDAQ: HSKA)

• Description: Heska Corporation, now part of Mars, provides veterinary diagnostics and imaging, enhancing animal healthcare with its Element™ platforms in 2025.

Hologic, Inc. (NASDAQ: HOLX)

• Description: Hologic, Inc. develops diagnostics and medical imaging, marketing Panther for molecular testing and advancing breast cancer detection technologies in 2025.

HOOKIPA Pharma Inc. (NASDAQ: HOOK)

• Description: HOOKIPA Pharma Inc. develops arenaviral immunotherapies, with HB-200 in Phase 2 trials for HPV16+ head and neck cancers, aiming to boost immune responses.

Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)

• Description: Horizon Therapeutics, now part of Amgen, markets TEPEZZA for thyroid eye disease and UPLIZNA for neuromyelitis optica, enhancing Amgen’s rare disease offerings in 2025.

Humanigen, Inc. (NASDAQ: HGEN)

• Description: Humanigen, Inc. develops lenzilumab, a monoclonal antibody for cytokine storm, with trials ongoing for CAR-T therapy side effects and chronic myelomonocytic leukemia in 2025.

HUTCHMED (China) Limited (NASDAQ: HCM)

• Description: HUTCHMED (China) Limited develops oncology and immunology therapies, marketing ELUNATE and SULANDA in China, with global trials expanding in 2025.

I-Mab (NASDAQ: IMAB)

• Description: I-Mab develops biologics for immuno-oncology, with lemzoparlimab in Phase 2 trials for solid tumors and autoimmune diseases, advancing its global pipeline.

IDEAYA Biosciences, Inc. (NASDAQ: IDYA)

• Description: IDEAYA Biosciences, Inc. develops precision oncology therapies, with IDE397 in Phase 2 trials for MTAP-deletion cancers and darovasertib for uveal melanoma.

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)

• Description: Idera Pharmaceuticals, Inc. focuses on toll-like receptor antagonists, with tilsotolimod in trials for melanoma and head and neck cancers, partnered with Bristol Myers Squibb.

Illumina, Inc. (NASDAQ: ILMN)

• Description: Illumina, Inc. provides genomic sequencing solutions, with NovaSeq™ and NextSeq™ platforms driving precision medicine and diagnostics in biotech research in 2025.

ImmunityBio, Inc. (NASDAQ: IBRX)

• Description: ImmunityBio, Inc. develops immunotherapies, with Anktiva (N-803) in Phase 3 trials for bladder cancer, aiming for FDA approval in 2025.

Immunocore Holdings plc (NASDAQ: IMCR)

• Description: Immunocore Holdings plc develops TCR therapies, marketing KIMMTRAK (tebentafusp) for uveal melanoma and advancing candidates for other cancers.

ImmunoGen, Inc. (NASDAQ: IMGN)

• Description: ImmunoGen, Inc., now part of AbbVie, markets ELAHERE (mirvetuximab soravtansine) for ovarian cancer, with AbbVie expanding its ADC platform in 2025.

Immunovant, Inc. (NASDAQ: IMVT)

• Description: Immunovant, Inc. develops therapies for autoimmune diseases, with batoclimab and IMVT-1402 in Phase 2/3 trials for myasthenia gravis and thyroid eye disease.

Incyte Corporation (NASDAQ: INCY)

• Description: Incyte Corporation develops oncology and dermatology therapies, marketing JAKAFI (ruxolitinib) and advancing its JAK inhibitor pipeline in 2025.

Inhibrx, Inc. (NASDAQ: INBX)

• Description: Inhibrx, Inc. develops biologics, with INBRX-101 in Phase 2 trials for alpha-1 antitrypsin deficiency, targeting protein replacement therapy advancements.

InMed Pharmaceuticals Inc. (NASDAQ: INM)

• Description: InMed Pharmaceuticals Inc. develops cannabinoid-based therapies, with INM-755 in trials for epidermolysis bullosa and INM-088 for glaucoma, progressing in 2025.

Inmune Bio, Inc. (NASDAQ: INMB)

• Description: Inmune Bio, Inc. develops immunotherapies, with XPro™ in Phase 2 trials for Alzheimer’s and NK cell therapies for cancer advancing in 2025.

Innovate Biopharmaceuticals, Inc. (NASDAQ: INNT)

• Description: Innovate Biopharmaceuticals, Inc., now 9 Meters Biopharma, develops therapies for GI disorders, with larazotide in trials for celiac disease and short bowel syndrome.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO)

• Description: Inovio Pharmaceuticals, Inc. develops DNA medicines, with INO-4800 in trials for COVID-19 and INO-3107 for HPV-related diseases, targeting approvals in 2025.

Inozyme Pharma, Inc. (NASDAQ: INZY)

• Description: Inozyme Pharma, Inc. develops therapies for rare mineralization disorders, with INZ-701 in Phase 1/2 trials for ENPP1 deficiency and ABCC6 deficiency.

Inspire Medical Systems, Inc. (NYSE: INSP)

• Description: Inspire Medical Systems, Inc. markets the Inspire therapy for obstructive sleep apnea, expanding its neurostimulation device adoption in sleep medicine in 2025.

Instil Bio, Inc. (NASDAQ: TIL)

• Description: Instil Bio, Inc. develops TIL therapies for solid tumors, with ITIL-306 in Phase 1 trials for lung and ovarian cancers, leveraging tumor-infiltrating lymphocytes.

Intellia Therapeutics, Inc. (NASDAQ: NTLA)

• Description: Intellia Therapeutics, Inc. develops CRISPR-based therapies, with NTLA-2001 in Phase 1/2 trials for transthyretin amyloidosis and NTLA-2002 for hereditary angioedema.

Intuitive Surgical, Inc. (NASDAQ: ISRG)

• Description: Intuitive Surgical, Inc. develops robotic surgical systems, with the da Vinci system leading minimally invasive surgery, expanding applications in 2025.

Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)

• Description: Ionis Pharmaceuticals, Inc. develops antisense therapies, marketing SPINRAZA for SMA and advancing eplontersen for ATTR amyloidosis in late-stage trials.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)

• Description: Iovance Biotherapeutics, Inc. develops TIL therapies, with lifileucel approved for advanced melanoma in 2024 and trials expanding to other cancers in 2025.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)

• Description: Ironwood Pharmaceuticals, Inc. markets LINZESS (linaclotide) for IBS-C and chronic constipation, with a pipeline targeting GI and metabolic disorders.

IsoRay, Inc. (NYSE American: ISR)

• Description: IsoRay, Inc., now Viewpoint Molecular Targeting, develops Cesium-131 brachytherapy for cancer, with expanded applications in prostate and brain tumors in 2025.

Jazz Pharmaceuticals plc (NASDAQ: JAZZ)

• Description: Jazz Pharmaceuticals plc markets XYREM for narcolepsy and EPIDIOLEX for epilepsy, with a pipeline advancing in oncology and neuroscience in 2025.

Karyopharm Therapeutics Inc. (NASDAQ: KPTI)

• Description: Karyopharm Therapeutics Inc. markets XPOVIO (selinexor) for multiple myeloma, with trials expanding its use in endometrial cancer and myelofibrosis.

Keros Therapeutics, Inc. (NASDAQ: KROS)

• Description: Keros Therapeutics, Inc. develops therapies for hematologic and musculoskeletal disorders, with KER-050 in Phase 2 trials for myelodysplastic syndromes.

Kezar Life Sciences, Inc. (NASDAQ: KZR)

• Description: Kezar Life Sciences, Inc. develops immunoproteasome inhibitors, with zetomipzomib in Phase 2 trials for lupus nephritis and autoimmune hepatitis in 2025.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA)

• Description: Kiniksa Pharmaceuticals, Ltd. markets ARCALYST (rilonacept) for recurrent pericarditis, with vixarelimab and abiprubart advancing for inflammatory diseases in trials.

Kinnate Biopharma Inc. (NASDAQ: KNTE)

• Description: Kinnate Biopharma Inc. develops kinase inhibitors, with exarafenib in Phase 1 trials for BRAF-mutated cancers, targeting precision oncology advancements.

Kodiak Sciences Inc. (NASDAQ: KOD)

• Description: Kodiak Sciences Inc. develops retinal therapies, with tarcocimab in Phase 3 trials for diabetic macular edema and wet AMD, leveraging its ABC Platform™.

Krystal Biotech, Inc. (NASDAQ: KRYS)

• Description: Krystal Biotech, Inc. markets VYJUVEK (beremagene geperpavec) for dystrophic epidermolysis bullosa, with a gene therapy pipeline expanding in 2025.

Kura Oncology, Inc. (NASDAQ: KURA)

• Description: Kura Oncology, Inc. develops precision oncology therapies, with ziftomenib in Phase 2 trials for NPM1-mutant AML, targeting regulatory milestones in 2025.

Kyowa Kirin Co., Ltd. (Tokyo: 4151.T)

• Description: Kyowa Kirin Co., Ltd. develops biologics, marketing POTELIGEO for T-cell lymphomas and advancing istradefylline for Parkinson’s in global markets in 2025.

Legend Biotech Corporation (NASDAQ: LEGN)

• Description: Legend Biotech Corporation markets CARVYKTI (ciltacabtagene autoleucel) for multiple myeloma, with trials expanding its CAR-T platform in 2025.

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX)

• Description: Lexicon Pharmaceuticals, Inc. develops small molecule drugs, with sotagliflozin in trials for heart failure and type 1 diabetes, targeting approvals in 2025.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

• Description: Ligand Pharmaceuticals Incorporated develops Captisol-enabled drugs, supporting biotech partners with its technology platform and advancing its internal pipeline.

Limbach Holdings, Inc. (NASDAQ: LMB)

• Description: Limbach Holdings, Inc., a building systems company, indirectly supports biotech through facility solutions, enhancing lab and manufacturing environments in 2025.

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX)

• Description: Lineage Cell Therapeutics, Inc. develops cell therapies, with OpRegen in trials for dry AMD and OPC1 for spinal cord injury advancing in 2025.

Lipocine Inc. (NASDAQ: LPCN)

• Description: Lipocine Inc. develops oral delivery therapies, with TLANDO (testosterone undecanoate) marketed for hypogonadism and LPCN 1144 in trials for NASH.

Liquidia Corporation (NASDAQ: LQDA)

• Description: Liquidia Corporation develops inhaled therapies using PRINT technology, with YUTREPIA™ (treprostinil) in trials for pulmonary arterial hypertension, targeting approval in 2025.

Luminary Therapeutics, Inc. (OTC: LMTX)

• Description: Luminary Therapeutics, Inc. develops cell therapies, with its BAFF CAR-T in preclinical stages for mantle cell lymphoma, leveraging multi-targeting approaches.

Lyra Therapeutics, Inc. (NASDAQ: LYRA)

• Description: Lyra Therapeutics, Inc. develops nasal therapies, with LYR-210 in Phase 3 trials for chronic rhinosinusitis, using its XTreo™ platform for sustained delivery.

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)

• Description: Madrigal Pharmaceuticals, Inc. develops resmetirom for NASH, with Phase 3 trials completed and potential FDA approval pending in 2025 for liver disease treatment.

MannKind Corporation (NASDAQ: MNKD)

• Description: MannKind Corporation markets AFREZZA (inhaled insulin) for diabetes, with its Technosphere platform expanding into pulmonary delivery for other therapies in 2025.

Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS)

• Description: Marinus Pharmaceuticals, Inc. markets ZTALMY (ganaxolone) for CDKL5 deficiency disorder, with trials expanding its use in epilepsy and tuberous sclerosis complex.

Matinas BioPharma Holdings, Inc. (NYSE American: MTNB)

• Description: Matinas BioPharma Holdings, Inc. develops lipid nanocrystal delivery, with MAT2203 (oral amphotericin B) in trials for fungal infections and a pipeline for chronic diseases.

Medpace Holdings, Inc. (NASDAQ: MEDP)

• Description: Medpace Holdings, Inc. provides clinical research services, supporting biotech drug development with full-service CRO capabilities in 2025.

Merck & Co., Inc. (NYSE: MRK)

• Description: Merck & Co., Inc. is a global biopharma leader, marketing KEYTRUDA (pembrolizumab) for cancer and advancing its oncology and vaccine pipeline in 2025.

Mersana Therapeutics, Inc. (NASDAQ: MRSN)

• Description: Mersana Therapeutics, Inc. develops ADC therapies, with upifitamab rilsodotin in Phase 1 trials for ovarian cancer, leveraging its Dolaflexin platform.

MiMedx Group, Inc. (NASDAQ: MDXG)

• Description: MiMedx Group, Inc. markets placental-based allografts like EPIFIX for wound care and osteoarthritis, with expanded applications in regenerative medicine in 2025.

Mirati Therapeutics, Inc. (NASDAQ: MRTX)

• Description: Mirati Therapeutics, Inc., now part of Bristol Myers Squibb, markets KRAZATI (adagrasib) for KRAS G12C-mutated cancers, enhancing BMS’s oncology portfolio in 2025.

Moderna, Inc. (NASDAQ: MRNA)

• Description: Moderna, Inc. pioneers mRNA therapies, marketing Spikevax for COVID-19 and advancing cancer and rare disease vaccines in late-stage trials in 2025.

Molecular Templates, Inc. (NASDAQ: MTEM)

• Description: Molecular Templates, Inc. develops engineered toxin bodies, with MT-6402 in Phase 1 trials for PD-L1-positive tumors, targeting immune checkpoint modulation.

Morphic Holding, Inc. (NASDAQ: MORF)

• Description: Morphic Holding, Inc. develops oral integrin therapies, with MORF-057 in Phase 2 trials for ulcerative colitis and Crohn’s disease, advancing in 2025.

Myovant Sciences Ltd. (NYSE: MYOV)

• Description: Myovant Sciences Ltd., now part of Sumitomo Pharma, markets ORGOVYX (relugolix) for prostate cancer and MYFEMBREE for women’s health, expanding under Sumitomo in 2025.

NantKwest, Inc. (NASDAQ: NK)

• Description: NantKwest, Inc., now ImmunityBio, markets Anktiva for bladder cancer, with its NK cell platform advancing in trials for other indications in 2025.

Natera, Inc. (NASDAQ: NTRA)

• Description: Natera, Inc. provides cfDNA testing, marketing Signatera™ for cancer recurrence monitoring and Prospera™ for transplant rejection, with expanded oncology applications in 2025.

Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)

• Description: Neoleukin Therapeutics, Inc. develops de novo protein therapeutics, with NL-201 in preclinical stages for cancer and inflammation, leveraging computational design.

NervGen Pharma Corp. (TSXV: NGEN)

• Description: NervGen Pharma Corp. develops NVG-291 for nerve regeneration, in Phase 1/2 trials for spinal cord injury and multiple sclerosis, targeting neural repair in 2025.

Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

• Description: Neurocrine Biosciences, Inc. markets INGREZZA (valbenazine) for tardive dyskinesia, with a pipeline advancing for epilepsy and Parkinson’s in 2025.

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM)

• Description: NGM Biopharmaceuticals, Inc. develops biologics for metabolic and oncology indications, with NGM707 in Phase 2 trials for solid tumors, partnered with Merck.

Nkarta, Inc. (NASDAQ: NKTX)

• Description: Nkarta, Inc. develops NK cell therapies, with NKX101 and NKX019 in Phase 1 trials for AML and lymphoma, leveraging engineered natural killer cells.

Nuvation Bio Inc. (NYSE: NUVB)

• Description: Nuvation Bio Inc. develops oncology therapies, with NUV-868 in Phase 1/2 trials for solid tumors, targeting BET proteins for cancer treatment.

Ocular Therapeutix, Inc. (NASDAQ: OCUL)

• Description: Ocular Therapeutix, Inc. markets DEXTENZA for ocular inflammation and develops OTX-TKI for wet AMD, with Phase 2 trials advancing in 2025.

Olema Pharmaceuticals, Inc. (NASDAQ: OLMA)

• Description: Olema Pharmaceuticals, Inc. develops therapies for women’s cancers, with OP-1250 in Phase 2 trials for ER+ breast cancer, targeting complete estrogen receptor antagonism.

OncoCyte Corporation (NASDAQ: OCX)

• Description: OncoCyte Corporation develops diagnostic tests, with DetermaRx™ for lung cancer treatment stratification and VitaGraft™ for transplant monitoring expanding in 2025.

Oncology Pharma Inc. (OTC: ONPH)

• Description: Oncology Pharma Inc. develops cancer therapies, with preclinical candidates leveraging nanotechnology for targeted drug delivery, progressing toward trials in 2025.

OncoSec Medical Incorporated (NASDAQ: ONCS)

• Description: OncoSec Medical Incorporated develops intratumoral immunotherapies, with TAVO™ (tavokinogene telseplasmid) in trials for melanoma and triple-negative breast cancer.

OPKO Health, Inc. (NASDAQ: OPK)

• Description: OPKO Health, Inc. markets RAYALDEE for secondary hyperparathyroidism and develops diagnostics and biologics, with a pipeline targeting growth hormone deficiencies.

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP)

• Description: Oramed Pharmaceuticals Inc. develops oral protein delivery, with ORMD-0801 in Phase 3 trials for type 2 diabetes, targeting insulin delivery innovation in 2025.

Organogenesis Holdings Inc. (NASDAQ: ORGO)

• Description: Organogenesis Holdings Inc. markets regenerative medicine products like Apligraf and PuraPly for wound care, expanding its advanced wound healing portfolio.

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC)

• Description: Oric Pharmaceuticals, Inc. develops therapies for resistant cancers, with ORIC-944 in Phase 1 trials for prostate cancer and glioblastoma, targeting PRC2 inhibition.

Otonomy, Inc. (NASDAQ: OTIC)

• Description: Otonomy, Inc. develops ear therapies, with OTO-313 in trials for tinnitus and OTO-413 for hearing loss, advancing its neurotology pipeline in 2025.

Oyster Point Pharma, Inc. (NASDAQ: OYST)

• Description: Oyster Point Pharma, Inc., now part of Viatris, markets TYRVAYA (varenicline nasal spray) for dry eye disease, enhancing Viatris’s eye care offerings in 2025.

Palisade Bio, Inc. (NASDAQ: PALI)

• Description: Palisade Bio, Inc. develops GI therapies, with LB1148 in Phase 2 trials to reduce post-surgical adhesions and accelerate GI recovery in 2025.

PAVmed Inc. (NASDAQ: PAVM)

• Description: PAVmed Inc. develops medical devices, with EsoGuard and EsoCheck for esophageal cancer detection and CarpX for carpal tunnel syndrome advancing in 2025.

PDS Biotechnology Corporation (NASDAQ: PDSB)

• Description: PDS Biotechnology Corporation develops Versamune-based immunotherapies, with PDS0101 in Phase 2 trials for HPV-associated cancers, targeting immune activation.

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)

• Description: Peregrine Pharmaceuticals, Inc., now Avid Bioservices, provides CDMO services for biotech, supporting drug development with manufacturing expertise in 2025.

Pfizer Inc. (NYSE: PFE)

• Description: Pfizer Inc. is a global biopharma leader, marketing PREVNAR vaccines and PAXLOVID for COVID-19, with a pipeline advancing in oncology and rare diseases.

PharmaCyte Biotech, Inc. (NASDAQ: PMCB)

• Description: PharmaCyte Biotech, Inc. develops cellular encapsulation therapies, with its lead candidate in trials for pancreatic cancer, leveraging its Cell-in-a-Box technology.

PhaseBio Pharmaceuticals, Inc. (NASDAQ: PHAS)

• Description: PhaseBio Pharmaceuticals, Inc. develops biopolymer-based therapies, with bentracimab in trials to reverse antiplatelet effects, advancing with SFJ Pharmaceuticals in 2025.

Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS)

• Description: Pieris Pharmaceuticals, Inc. develops Anticalin proteins, with cinrebafusp alfa in trials for HER2-positive cancers, partnered with Seagen and others.

Pliant Therapeutics, Inc. (NASDAQ: PLRX)

• Description: Pliant Therapeutics, Inc. develops therapies for fibrosis, with bexotegrast in Phase 2b trials for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Pluristem Therapeutics Inc. (NASDAQ: PSTI)

• Description: Pluristem Therapeutics Inc., now Pluri Inc., develops PLX cell therapies for inflammatory and hematologic conditions, with trials advancing in 2025.

Point Biopharma Global Inc. (NASDAQ: PNT)
Description: Point Biopharma Global Inc., now part of Eli Lilly, develops radiopharmaceuticals like PNT2002 for prostate cancer, with its PSMA-targeted therapies advancing in late-stage trials under Lilly’s oncology expansion in 2025.

Poseida Therapeutics, Inc. (NASDAQ: PSTX)
Description: Poseida Therapeutics, Inc. develops allogeneic CAR-T therapies, with P-BCMA-ALLO1 in Phase 1 trials for multiple myeloma, leveraging its non-viral gene editing platform.

Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
Description: Praxis Precision Medicines, Inc. focuses on CNS disorders, with PRAX-114 in trials for epilepsy and depression, aiming for precision neuroscience breakthroughs in 2025.

Precision BioSciences, Inc. (NASDAQ: DTIL)
Description: Precision BioSciences, Inc. uses ARCUS gene editing for oncology and genetic diseases, with PBGENE-HBV in preclinical stages for hepatitis B cure targeting 2025 trials.

Prevail Therapeutics Inc. (NASDAQ: PRVL)
Description: Prevail Therapeutics Inc., now part of Eli Lilly, advances gene therapies like PR001 for Parkinson’s with GBA1 mutations, integrating into Lilly’s neurology pipeline in 2025.

Progenity, Inc. (NASDAQ: PROG)
Description: Progenity, Inc., now Biora Therapeutics, develops oral biotherapeutics, with its Drug Delivery System in trials for ulcerative colitis, targeting GI precision medicine in 2025.

ProQR Therapeutics N.V. (NASDAQ: PRQR)
Description: ProQR Therapeutics N.V. develops RNA therapies for rare diseases, with sepofarsen in trials for Leber congenital amaurosis and QR-421a for Usher syndrome advancing in 2025.

Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
Description: Protagonist Therapeutics, Inc. develops peptide-based drugs, with rusfertide in Phase 3 for polycythemia vera and PN-943 for ulcerative colitis nearing key milestones.

Proteostasis Therapeutics, Inc. (NASDAQ: PTI)
Description: Proteostasis Therapeutics, Inc., now Yumanity Therapeutics under new ownership, focuses on neurodegenerative diseases, with YTX-7739 in trials for Parkinson’s in 2025.

Prothena Corporation plc (NASDAQ: PRTA)
Description: Prothena Corporation plc develops protein misfolding therapies, with birtamimab in Phase 3 for AL amyloidosis and prasinezumab for Parkinson’s advancing with Roche.

Puma Biotechnology, Inc. (NASDAQ: PBYI)
Description: Puma Biotechnology, Inc. markets NERLYNX (neratinib) for HER2+ breast cancer, with trials exploring new indications in solid tumors for 2025 growth.

PureTech Health plc (NASDAQ: PRTC)
Description: PureTech Health plc develops therapies via subsidiaries, with Karuna’s KarXT for schizophrenia nearing approval and LYT-100 for lymphedema in trials by 2025.

Pyxis Oncology, Inc. (NASDAQ: PYXS)
Description: Pyxis Oncology, Inc. develops ADCs and immunotherapies, with PYX-201 in Phase 1 for solid tumors, targeting novel cancer pathways in 2025.

Q32 Bio Inc. (NASDAQ: QTTB)
Description: Q32 Bio Inc. develops biologics for autoimmune diseases, with ADX-097 in Phase 2 trials for complement-mediated disorders, advancing immune modulation in 2025.

Radius Health, Inc. (NASDAQ: RDUS)
Description: Radius Health, Inc., now part of Gedeon Richter, markets TYMLOS (abaloparatide) for osteoporosis, with expanded women’s health applications in 2025.

Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)
Description: Rani Therapeutics Holdings, Inc. develops oral biologics delivery, with its RaniPill in trials for osteoporosis and psoriasis, targeting needle-free administration in 2025.

Rapport Therapeutics, Inc. (NASDAQ: RAPT)
Description: Rapport Therapeutics, Inc. develops small molecule drugs for CNS disorders, with RAP-219 in preclinical stages for epilepsy and pain, advancing toward trials in 2025.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
Description: Regeneron Pharmaceuticals, Inc. markets EYLEA for eye diseases and LIBTAYO for cancer, with its antibody and gene therapy pipeline expanding in 2025.

REGENXBIO Inc. (NASDAQ: RGNX)
Description: REGENXBIO Inc. develops AAV gene therapies, with RGX-314 in Phase 3 for wet AMD and RGX-202 for Duchenne muscular dystrophy nearing key data in 2025.

Relay Therapeutics, Inc. (NASDAQ: RLAY)
Description: Relay Therapeutics, Inc. uses computational drug design, with RLY-2608 in Phase 1 for PI3Kα-mutated cancers, targeting precision oncology milestones in 2025.

Repligen Corporation (NASDAQ: RGEN)
Description: Repligen Corporation provides bioprocessing solutions, with its filtration and chromatography systems supporting biotech manufacturing scale-ups in 2025.

Repare Therapeutics Inc. (NASDAQ: RPTX)
Description: Repare Therapeutics Inc. develops synthetic lethality therapies, with RP-6306 in Phase 1 for solid tumors, advancing its precision oncology platform in 2025.

Replimune Group, Inc. (NASDAQ: REPL)
Description: Replimune Group, Inc. develops oncolytic immunotherapies, with RP1 in Phase 2 for melanoma and RP2 for solid tumors, targeting approvals by 2025.

ResMed Inc. (NYSE: RMD)
Description: ResMed Inc. markets sleep apnea devices like AirSense™ and cloud-connected ventilators, expanding digital health integrations for respiratory care in 2025.

Retrophin, Inc. (NASDAQ: RTRX)
Description: Retrophin, Inc., now Travere Therapeutics, markets THIOLA for cystinuria and sparsentan in Phase 3 for FSGS and IgA nephropathy, nearing approvals in 2025.

Revolution Medicines, Inc. (NASDAQ: RVMD)
Description: Revolution Medicines, Inc. develops RAS-targeted therapies, with RMC-6236 in Phase 1 for KRAS-mutated cancers, aiming for broad oncology impact in 2025.

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)
Description: Rigel Pharmaceuticals, Inc. markets TAVALISSE (fostamatinib) for ITP and REZLIDHIA for AML, with its kinase inhibitor pipeline growing in 2025.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)
Description: Rocket Pharmaceuticals, Inc. develops gene therapies, with RP-L201 in Phase 2 for LAD-I and RP-A501 for Danon disease, targeting rare disease cures in 2025.

Roivant Sciences Ltd. (NASDAQ: ROIV)
Description: Roivant Sciences Ltd. advances therapies via Vants, with brepocitinib for dermatomyositis and tapinarof for psoriasis in late-stage trials for 2025 launches.

Rubius Therapeutics, Inc. (NASDAQ: RUBY)
Description: Rubius Therapeutics, Inc., now restructured, develops red cell therapeutics, with RTX-240 in trials for AML and solid tumors, aiming for allogeneic solutions in 2025.

Sage Therapeutics, Inc. (NASDAQ: SAGE)
Description: Sage Therapeutics, Inc. markets ZULRESSO for postpartum depression, with zuranolone in trials for MDD and PPD, targeting broader CNS approvals in 2025.

Sana Biotechnology, Inc. (NASDAQ: SANA)
Description: Sana Biotechnology, Inc. develops engineered cell therapies, with SC291 in Phase 1 for B-cell malignancies, advancing hypoimmune platforms in 2025.

Sangamo Therapeutics, Inc. (NASDAQ: SGMO)
Description: Sangamo Therapeutics, Inc. pioneers genomic medicines, with ST-920 in Phase 1/2 for Fabry disease and zinc finger therapies for hemophilia advancing.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT)
Description: Sarepta Therapeutics, Inc. markets EXONDYS 51 for DMD, with SRP-9001 in Phase 3 for broader DMD genotypes, eyeing approvals in 2025.

Scholar Rock Holding Corporation (NASDAQ: SRRK)
Description: Scholar Rock Holding Corporation develops TGFβ inhibitors, with apitegromab in Phase 3 for SMA and SRK-439 for obesity in preclinical stages for 2025.

Sculptor Capital Management, Inc. (NYSE: SCU)
Description: Sculptor Capital Management, Inc. invests in biotech through hedge funds, supporting early-stage medical tech innovations with capital in 2025.

Seagen Inc. (NASDAQ: SGEN)
Description: Seagen Inc., now part of Pfizer, markets ADCETRIS for lymphomas and PADCEV for bladder cancer, with its ADC platform expanding under Pfizer in 2025.

Selecta Biosciences, Inc. (NASDAQ: SELB)
Description: Selecta Biosciences, Inc., now Cartesian Therapeutics, develops ImmTOR-enhanced gene therapies, with Descartes-08 in Phase 2 for myasthenia gravis in 2025.

Seres Therapeutics, Inc. (NASDAQ: MCRB)
Description: Seres Therapeutics, Inc. markets SER-109 for recurrent C. diff infection, with SER-155 in trials for GvHD, advancing microbiome therapies in 2025.

Sesen Bio, Inc. (NASDAQ: SESN)
Description: Sesen Bio, Inc., now Carisma Therapeutics, develops CAR-M therapies, with CT-0508 in Phase 1 for HER2+ solid tumors, shifting to macrophage-based approaches.

Shattuck Labs, Inc. (NASDAQ: STTK)
Description: Shattuck Labs, Inc. develops Agonist Redirected Checkpoint therapies, with SL-172154 in Phase 1 for ovarian cancer, targeting dual immune activation in 2025.

Shionogi & Co., Ltd. (Tokyo: 4507.T)
Description: Shionogi & Co., Ltd. markets XOFLUZA for influenza and advances cefiderocol for bacterial infections, with a growing global biotech presence in 2025.

Sierra Oncology, Inc. (NASDAQ: SRRA)
Description: Sierra Oncology, Inc., now part of GSK, markets momelotinib for myelofibrosis, enhancing GSK’s hematology portfolio with JAK inhibitor therapies in 2025.

SIGA Technologies, Inc. (NASDAQ: SIGA)
Description: SIGA Technologies, Inc. markets TPOXX (tecovirimat) for smallpox, with expanded biodefense contracts and antiviral research growing in 2025.

Silence Therapeutics plc (NASDAQ: SLN)
Description: Silence Therapeutics plc develops siRNA therapies, with SLN360 in Phase 2 for cardiovascular disease and SLN124 for thalassemia, advancing in 2025.

Sio Gene Therapies Inc. (NASDAQ: SIOX)
Description: Sio Gene Therapies Inc., now restructured, advances AXO-Lenti-PD for Parkinson’s and AXO-AAV-GM1 for GM1 gangliosidosis, targeting rare disease markets in 2025.

Sorrento Therapeutics, Inc. (NASDAQ: SRNE)
Description: Sorrento Therapeutics, Inc. develops CAR-T and antibody therapies, with sofusa lymphatic delivery in trials for cancer and autoimmune diseases in 2025.

Sotera Health Company (NASDAQ: SHC)
Description: Sotera Health Company provides sterilization and lab services for biotech, with its Sterigenics and Nordion units supporting medical device production in 2025.

Spark Therapeutics, Inc. (NASDAQ: ONCE)
Description: Spark Therapeutics, Inc., now part of Roche, markets LUXTURNA for retinal dystrophy and advances hemophilia gene therapies under Roche’s umbrella in 2025.

Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Description: Spectrum Pharmaceuticals, Inc., now restructured, markets ROLONTIS for neutropenia, with its oncology pipeline refocused on niche markets in 2025.

SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
Description: SpringWorks Therapeutics, Inc. markets OGSIVEO (nirogacestat) for desmoid tumors, with mirdametinib in Phase 2 for NF1-PN, targeting rare cancers in 2025.

Spero Therapeutics, Inc. (NASDAQ: SPRO)
Description: Spero Therapeutics, Inc. develops antibiotics, with tebipenem HBr in Phase 3 for cUTI and SPR720 for NTM infections, addressing resistance in 2025.

Stoke Therapeutics, Inc. (NASDAQ: STOK)
Description: Stoke Therapeutics, Inc. develops antisense therapies, with STK-001 in Phase 2 for Dravet syndrome and STK-002 for autosomal dominant optic atrophy in 2025.

Summit Therapeutics Inc. (NASDAQ: SMMT)
Description: Summit Therapeutics Inc. develops ridinilazole for C. diff infection and ivonescimab for lung cancer, with Phase 3 trials advancing rapidly in 2025.

Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
Description: Supernus Pharmaceuticals, Inc. markets QELBREE for ADHD and TROKENDI XR for epilepsy, with a CNS pipeline expanding in pediatric indications.

Surface Oncology, Inc. (NASDAQ: SURF)
Description: Surface Oncology, Inc., now part of Coherus BioSciences, develops SRF388 for liver cancer and SRF114 for solid tumors, enhancing Coherus’s oncology offerings.

Sutro Biopharma, Inc. (NASDAQ: STRO)
Description: Sutro Biopharma, Inc. develops ADCs and bispecifics, with STRO-002 in Phase 1 for ovarian cancer, leveraging its cell-free protein synthesis platform.

Syros Pharmaceuticals, Inc. (NASDAQ: SYRS)
Description: Syros Pharmaceuticals, Inc. develops gene control therapies, with tamibarotene in Phase 3 for MDS and SY-5609 for pancreatic cancer in trials for 2025.

Takeda Pharmaceutical Company Limited (NYSE: TAK)
Description: Takeda Pharmaceutical Company Limited markets ENTYVIO for IBD and TAKHZYRO for HAE, with a broad pipeline in oncology and rare diseases in 2025.

Talaris Therapeutics, Inc. (NASDAQ: TALS)
Description: Talaris Therapeutics, Inc., now restructured as Tourmaline Bio, develops FCR001 for transplant tolerance and TRB-101 for autoimmune diseases in 2025.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
Description: Tandem Diabetes Care, Inc. markets t:slim X2™ insulin pumps, with integrations like Control-IQ enhancing diabetes management tech in 2025.

Taysha Gene Therapies, Inc. (NASDAQ: TSHA)
Description: Taysha Gene Therapies, Inc. develops AAV therapies, with TSHA-120 for GAN and TSHA-102 for Rett syndrome in Phase 1/2 trials aiming for 2025 milestones.

Teladoc Health, Inc. (NYSE: TDOC)
Description: Teladoc Health, Inc. provides telemedicine platforms, integrating AI-driven diagnostics and chronic care management for biotech synergies in 2025.

Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
Description: Terns Pharmaceuticals, Inc. develops small molecule drugs, with TERN-701 in Phase 1 for CML and TERN-601 for obesity, targeting metabolic diseases in 2025.

Tessa Therapeutics Ltd. (Private, potential IPO)
Description: Tessa Therapeutics Ltd. develops CAR-T therapies, with TT11 in Phase 2 for Hodgkin lymphoma, eyeing a public listing and approvals by 2025.

TherapeuticsMD, Inc. (NASDAQ: TXMD)
Description: TherapeuticsMD, Inc. markets ANNOVERA for contraception and IMVEXXY for menopause, with women’s health innovations continuing in 2025.

Theravance Biopharma, Inc. (NASDAQ: TBPH)
Description: Theravance Biopharma, Inc. markets YUPELRI for COPD, with ampreloxetine in Phase 3 for neurogenic orthostatic hypotension advancing in 2025.

Thermo Fisher Scientific Inc. (NYSE: TMO)
Description: Thermo Fisher Scientific Inc. provides biotech tools like sequencing platforms and reagents, driving drug discovery and diagnostics in 2025.

Titan Pharmaceuticals, Inc. (NASDAQ: TTNP)
Description: Titan Pharmaceuticals, Inc. develops ProNeura implants, with Probuphine for opioid dependence and new candidates for chronic diseases in trials.

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)
Description: Tonix Pharmaceuticals Holding Corp. develops TNX-102 SL for fibromyalgia and TNX-1300 for cocaine intoxication, with Phase 3 trials progressing in 2025.

Tracon Pharmaceuticals, Inc. (NASDAQ: TCON)
Description: Tracon Pharmaceuticals, Inc. develops envafolimab for sarcoma and TRC102 for lung cancer, with Phase 2 trials targeting niche oncology markets.

Translate Bio, Inc. (NASDAQ: TBIO)
Description: Translate Bio, Inc., now part of Sanofi, advances mRNA therapies like MRT5005 for cystic fibrosis, enhancing Sanofi’s rare disease portfolio in 2025.

Travere Therapeutics, Inc. (NASDAQ: TVTX)
Description: Travere Therapeutics, Inc. markets THIOLA for cystinuria, with sparsentan in Phase 3 for FSGS and IgAN, nearing potential approvals in 2025.

Trevi Therapeutics, Inc. (NASDAQ: TRVI)
Description: Trevi Therapeutics, Inc. develops Haduvio™ (nalbuphine ER) for chronic pruritus and cough, with Phase 2b/3 trials advancing for 2025 readouts.

Tricida, Inc. (NASDAQ: TCDA)
Description: Tricida, Inc., restructured post-bankruptcy, focuses on veverimer for metabolic acidosis in CKD, with a leaner pipeline targeting niche markets in 2025.

Trillium Therapeutics Inc. (NASDAQ: TRIL)
Description: Trillium Therapeutics Inc., now part of Pfizer, advances CD47-targeted therapies like TTI-622 for hematologic cancers, integrated into Pfizer’s oncology lineup.

Trinity Biotech plc (NASDAQ: TRIB)
Description: Trinity Biotech plc develops diagnostics for diabetes and infectious diseases, with its rapid HIV tests and CGM tech expanding in 2025.

TScan Therapeutics, Inc. (NASDAQ: TCRX)
Description: TScan Therapeutics, Inc. develops TCR-T therapies, with TSC-100 and TSC-101 in Phase 1 for AML and MDS, targeting post-transplant relapse.

TumorGenix Inc. (Private, potential IPO)
Description: TumorGenix Inc. develops tumor microenvironment therapies, with preclinical candidates for solid tumors, eyeing a public debut by 2025.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX)
Description: Turning Point Therapeutics, Inc., now part of Bristol Myers Squibb, markets repotrectinib for ROS1+ NSCLC, enhancing BMS’s precision oncology in 2025.

Twist Bioscience Corporation (NASDAQ: TWST)
Description: Twist Bioscience Corporation provides synthetic DNA for biotech, with its silicon-based platform supporting drug discovery and antibody development in 2025.

UCB S.A. (Euronext Brussels: UCB.BR)
Description: UCB S.A. markets CIMZIA for autoimmune diseases and BIMZELX for psoriasis, with a neurology and immunology pipeline growing in 2025.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
Description: Ultragenyx Pharmaceutical Inc. markets Crysvita for XLH and Mepsevii for MPS VII, with gene therapies like UX701 for Wilson disease in trials.

UniQure N.V. (NASDAQ: QURE)
Description: UniQure N.V. markets AMT-061 (Etranacogene Dezaparvovec) for hemophilia B, with AMT-130 for Huntington’s disease in Phase 1/2 trials for 2025.

Unity Biotechnology, Inc. (NASDAQ: UBX)
Description: Unity Biotechnology, Inc. develops senolytic therapies, with UBX1325 in Phase 2 for diabetic macular edema, targeting age-related diseases in 2025.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA)
Description: Vanda Pharmaceuticals Inc. markets HETLIOZ for sleep disorders and FANAPT for schizophrenia, with tradipitant in trials for gastroparesis in 2025.

Vaxart, Inc. (NASDAQ: VXRT)
Description: Vaxart, Inc. develops oral vaccines, with its norovirus and COVID-19 candidates in Phase 2 trials, leveraging its tablet-based platform in 2025.

VBI Vaccines Inc. (NASDAQ: VBIV)
Description: VBI Vaccines Inc. markets Sci-B-Vac for hepatitis B, with VBI-2601 in trials for HBV and glioblastoma vaccines advancing in 2025.

VBL Therapeutics (NASDAQ: VB-111)
Description: VBL Therapeutics develops VB-111 for ovarian cancer and glioblastoma, with Phase 3 trials targeting vascular disruption in solid tumors for 2025.

Veracyte, Inc. (NASDAQ: VCYT)
Description: Veracyte, Inc. provides genomic diagnostics, with Afirma for thyroid cancer and Decipher for prostate cancer expanding precision medicine in 2025.

Vera Therapeutics, Inc. (NASDAQ: VERA)
Description: Vera Therapeutics, Inc. develops atacicept for IgA nephropathy and MAU868 for BK virus in transplant patients, with Phase 2/3 trials progressing in 2025.

Verastem, Inc. (NASDAQ: VSTM)
Description: Verastem, Inc. develops RAS pathway inhibitors, with avutometinib and defactinib in Phase 2 for low-grade serous ovarian cancer, targeting 2025 approvals.

Vericel Corporation (NASDAQ: VCEL)
Description: Vericel Corporation markets MACI for cartilage repair and Epicel for burns, with NexoBrid expanding its regenerative medicine portfolio in 2025.

Verona Pharma plc (NASDAQ: VRNA)
Description: Verona Pharma plc develops ensifentrine for COPD, with Phase 3 trials completed and potential FDA approval pending in 2025 for respiratory care.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
Description: Vertex Pharmaceuticals Incorporated markets TRIKAFTA for cystic fibrosis, with VX-548 for pain and gene editing therapies advancing in 2025.

Verve Therapeutics, Inc. (NASDAQ: VERV)
Description: Verve Therapeutics, Inc. develops base editing therapies, with VERVE-101 in Phase 1 for heterozygous FH, targeting cardiovascular disease in 2025.

Viatris Inc. (NASDAQ: VTRS)
Description: Viatris Inc. markets biosimilars and generics, with YUPELRI for COPD and TYRVAYA for dry eye enhancing its specialty portfolio in 2025.

Viking Therapeutics, Inc. (NASDAQ: VKTX)
Description: Viking Therapeutics, Inc. develops VK2809 for NASH and VK2735 for obesity, with Phase 2b trials showing promise for metabolic disease treatments in 2025.

Vir Biotechnology, Inc. (NASDAQ: VIR)
Description: Vir Biotechnology, Inc. develops VIR-7831 for hepatitis B and tobevibart for HIV, with Phase 2/3 trials advancing infectious disease solutions in 2025.

Viridian Therapeutics, Inc. (NASDAQ: VRDN)
Description: Viridian Therapeutics, Inc. develops VRDN-001 for thyroid eye disease, with Phase 3 trials underway and potential approvals targeted for 2025.

Vistagen Therapeutics, Inc. (NASDAQ: VTGN)
Description: Vistagen Therapeutics, Inc. develops PH94B for anxiety and PH10 for depression, with Phase 3 trials advancing rapid-acting neuropsychiatric therapies.

Viveve Medical, Inc. (NASDAQ: VIVE)
Description: Viveve Medical, Inc. markets radiofrequency devices for women’s health, with Viveve System expanding into sexual dysfunction treatments in 2025.

Vivos Therapeutics, Inc. (NASDAQ: VVOS)
Description: Vivos Therapeutics, Inc. markets oral appliances for sleep apnea, with its Vivos Method gaining traction in non-invasive sleep solutions in 2025.

Voyager Therapeutics, Inc. (NASDAQ: VYGR)
Description: Voyager Therapeutics, Inc. develops AAV gene therapies, with VY-HTT01 for Huntington’s and VY-SOD102 for ALS in preclinical stages for 2025 trials.

Wave Life Sciences Ltd. (NASDAQ: WVE)
Description: Wave Life Sciences Ltd. develops stereopure oligonucleotides, with WVE-003 for Huntington’s and WVE-N531 for DMD in Phase 1/2 trials.

Werewolf Therapeutics, Inc. (NASDAQ: HOWL)
Description: Werewolf Therapeutics, Inc. develops cytokine therapies, with WTX-124 in Phase 1 for solid tumors, leveraging its PREDATOR™ platform in 2025.

X4 Pharmaceuticals, Inc. (NASDAQ: XFOR)
Description: X4 Pharmaceuticals, Inc. markets XOLREMDI™ (mavorixafor) for WHIM syndrome, with trials expanding to chronic neutropenia in 2025.

XBiotech Inc. (NASDAQ: XBIT)
Description: XBiotech Inc. develops IL-1α antibodies, with bermekimab in trials for inflammatory diseases and oncology, targeting niche therapeutic markets.

Xencor, Inc. (NASDAQ: XNCR)
Description: Xencor, Inc. develops XmAb bispecifics, with vibecotamab for AML and plamotamab for lymphoma in Phase 1 trials advancing in 2025.

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS)
Description: Xeris Biopharma Holdings, Inc. markets Gvoke for hypoglycemia, with XP-8121 for endocrine disorders in trials using its XeriSol™ platform.

XOMA Corporation (NASDAQ: XOMA)
Description: XOMA Corporation acquires royalty interests in biotech, with its portfolio including assets from Novartis and Takeda, generating revenue in 2025.

Y-mAbs Therapeutics, Inc. (NASDAQ YMAB)
Description: Y-mAbs Therapeutics, Inc. markets DANYELZA for neuroblastoma, with omburtamab in trials for CNS metastasis, targeting pediatric cancers in 2025.

Zai Lab Limited (NASDAQ: ZLAB)
Description: Zai Lab Limited markets ZEJULA for ovarian cancer in China, with a pipeline advancing oncology and autoimmune therapies globally in 2025.

Zealand Pharma A/S (NASDAQ: ZEAL)
Description: Zealand Pharma A/S develops peptide therapies, with dasiglucagon for hypoglycemia and glepaglutide for short bowel syndrome in late-stage trials.

Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL)
Description: Zentalis Pharmaceuticals, Inc. develops ZN-c3 for solid tumors and ZN-d5 for lymphoma, with Phase 2 trials targeting Wee1 and BCL-2 inhibition in 2025.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
Description: Zimmer Biomet Holdings, Inc. markets orthopedic implants and ROSA robotics, with smart implants enhancing surgical precision in 2025.

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP)
Description: ZIOPHARM Oncology, Inc., now Alaunos Therapeutics, develops TCR-T therapies, with its Sleeping Beauty platform in trials for solid tumors in 2025.

Zogenix, Inc. (NASDAQ: ZGNX)
Description: Zogenix, Inc., now part of UCB, markets FINTEPLA for Dravet syndrome, with UCB expanding its epilepsy portfolio in 2025.

Zymeworks Inc. (NASDAQ: ZYME)
Description: Zymeworks Inc. develops zanidatamab for HER2+ cancers and ZW49 for solid tumors, with Phase 2/3 trials advancing bispecific antibody platforms.

TOP